These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 11460392)

  • 21. [Type 2 diabetic patient with kidney damage. Sartans banish dialysis risk].
    MMW Fortschr Med; 2004 Jul; 146(27-28):56. PubMed ID: 15526676
    [No Abstract]   [Full Text] [Related]  

  • 22. [Microalbuminuria in patients with hypertension and cardiovascular comorbidity, REAL observational study of treatment with Irbesartan/HCTZ].
    Tschöpe C; Tschöpe R; Unger T
    MMW Fortschr Med; 2006 Jun; 148(25):48. PubMed ID: 16859162
    [No Abstract]   [Full Text] [Related]  

  • 23. Renal protection by angiotensin II receptor antagonists in patients with type 2 diabetes.
    Jerums G; Cooper ME; Gilbert RE; Atkins RC
    Med J Aust; 2001 Oct; 175(8):397-9. PubMed ID: 11700829
    [No Abstract]   [Full Text] [Related]  

  • 24. [Dangerous deficits in management of hypertensive diabetic patients. A kidney check is far from standard procedure].
    MMW Fortschr Med; 2003 Apr; 145(17):55. PubMed ID: 12808810
    [No Abstract]   [Full Text] [Related]  

  • 25. Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy.
    Jacobsen P; Andersen S; Rossing K; Jensen BR; Parving HH
    Kidney Int; 2003 May; 63(5):1874-80. PubMed ID: 12675866
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Renoprotection by blockade of the renin-angiotensin-aldosterone system in diabetic and non-diabetic chronic kidney disease. Specific involvement of intra-renal angiotensin-converting enzyme activity in therapy resistance?
    Vogt L; Kocks MJ; Laverman GD; Navis G
    Minerva Med; 2004 Oct; 95(5):395-409. PubMed ID: 15467515
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
    Brenner BM; Cooper ME; de Zeeuw D; Keane WF; Mitch WE; Parving HH; Remuzzi G; Snapinn SM; Zhang Z; Shahinfar S;
    N Engl J Med; 2001 Sep; 345(12):861-9. PubMed ID: 11565518
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Diabetic patient with hypertension takes A-I I blocker. Less likely dialysis].
    MMW Fortschr Med; 2002 Feb; 144(8):52. PubMed ID: 11910830
    [No Abstract]   [Full Text] [Related]  

  • 29. [The RENAAL Study. Effect of losartan on diabetic nephropathy].
    Kuhlmann MK; Köhler H
    Internist (Berl); 2002 May; 43(5):675-7. PubMed ID: 12085539
    [No Abstract]   [Full Text] [Related]  

  • 30. Antiproteinuric effect of candesartan cilexetil in Japanese subjects with type 2 diabetes and nephropathy.
    Haneda M; Kikkawa R; Sakai H; Kawamori R;
    Diabetes Res Clin Pract; 2004 Oct; 66(1):87-95. PubMed ID: 15364166
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Drug companies should not have the final say in the design of clinical trials.
    Kurtzman NA
    Am J Kidney Dis; 2001 Nov; 38(5):1113-4. PubMed ID: 11684568
    [No Abstract]   [Full Text] [Related]  

  • 32. [Current treatment of diabetic nephropathy in patients with type II diabetes mellitus. Most recent progress].
    de Alvaro F
    Nefrologia; 2001; 21 Suppl 3():76-82. PubMed ID: 11642211
    [No Abstract]   [Full Text] [Related]  

  • 33. [Effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes].
    Parving HH; Lehnert H; Brøchner-Mortensen J; Gomis R; Andersen S; Arner P
    Ugeskr Laeger; 2001 Oct; 163(40):5519-24. PubMed ID: 11601118
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combination antihypertensive therapy in the treatment of diabetic nephropathy.
    Boner G; Cao Z; Cooper ME
    Diabetes Technol Ther; 2002; 4(3):313-21. PubMed ID: 12165170
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A new class of antihypertensive: angiotensin II receptor antagonists.
    McCoy R
    S D J Med; 1995 Sep; 48(9):319-20. PubMed ID: 7481726
    [No Abstract]   [Full Text] [Related]  

  • 36. Advances in the treatment of diabetic renal disease: focus on losartan.
    Rayner B
    Curr Med Res Opin; 2004 Mar; 20(3):333-40. PubMed ID: 15025842
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Renoprotection in Type 2 diabetes: blockade of the renin-angiotensin system with angiotensin II receptor blockers.
    Swift PA; MacGregor GA
    J Renin Angiotensin Aldosterone Syst; 2001 Sep; 2(3):170-3. PubMed ID: 11881118
    [No Abstract]   [Full Text] [Related]  

  • 38. Irbesartan treatment of patients with type 2 diabetes, hypertension and renal disease: a UK health economics analysis.
    Palmer AJ; Valentine WJ; Ray JA
    Int J Clin Pract; 2007 Oct; 61(10):1626-33. PubMed ID: 17877649
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Acute oliguric renal failure associated with angiotensin II receptor antagonists.
    Lee HY; Kim CH
    Am J Med; 2001 Aug; 111(2):162-3. PubMed ID: 11501548
    [No Abstract]   [Full Text] [Related]  

  • 40. [Valsartan: arguments for the high dose concept].
    MMW Fortschr Med; 2006 Dec; 148(51-52):54-5. PubMed ID: 17619348
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.